Company Filing History:
Years Active: 2001
Title: Soumitra Basu: Innovator in Peptide Nucleic Acid Conjugates
Introduction
Soumitra Basu is a notable inventor based in New Haven, CT (US). She has made significant contributions to the field of biotechnology, particularly in the development of peptide nucleic acid (PNA) conjugates. Her innovative work focuses on enhancing cellular uptake of PNA oligomers, which has important implications for genetic research and therapeutic applications.
Latest Patents
Soumitra Basu holds a patent for her invention titled "Peptide nucleic acid conjugates." This patent describes a method where PNA oligomers are conjugated to a ligand capable of binding to a cell surface receptor. The ligand facilitates the cellular uptake of the PNA oligomer. When the ligand is a peptide, the conjugate can be produced as a unitary molecule by synthesizing the peptide ligand through solid phase or solution peptide synthesis, followed by the synthesis of the PNA oligomer as an extension of the peptide ligand. The base sequence of the PNA oligomer is selected to hybridize to a target polynucleotide sequence through either triplex (dsDNA) or duplex (ssDNA; RNA) formation. This innovative approach has the potential to advance the field of molecular biology.
Career Highlights
Soumitra Basu is affiliated with Thomas Jefferson University, where she continues her research and development in the field of biotechnology. Her work has garnered attention for its potential applications in therapeutic interventions and genetic research.
Collaborations
One of her notable collaborators is Eric Wickstrom, who works alongside her in her research endeavors. Their combined expertise contributes to the advancement of their projects and the exploration of new scientific frontiers.
Conclusion
Soumitra Basu's contributions to the field of peptide nucleic acid conjugates exemplify her innovative spirit and dedication to advancing biotechnology. Her work not only enhances our understanding of molecular interactions but also paves the way for future therapeutic developments.